Objective-Engagement of intercellular adhesion molecule 1 (ICAM-1) on endothelial cells by ICAM-1-targeted carriers induces cell adhesion molecule-mediated endocytosis, providing intraendothelial delivery of therapeutics. This pathway differs from classical endocytic mechanisms and invokes aspects of endothelial signaling during inflammation. ICAM-1 interacts with Na 1 /H 1 exchanger NHE1 during endocytosis, but it is unclear how this regulates plasmalemma and cytoskeletal changes. We studied such aspects in this work. Methods and Results-We used fluorescence and electron microscopy, inhibitors and knockout tools, cell culture, and mouse models. ICAM-1 engagement by anti-ICAM carriers induced sphingomyelin-enriched engulfment structures. Acid sphingomyelinase (ASM), an acidic enzyme that hydrolyzes sphingomyelin into ceramide (involved in plasmalemma deformability and cytoskeletal reorganization), redistributed to ICAM-1-engagement sites at ceramide-enriched areas. This induced actin stress fibers and carrier endocytosis. Inhibiting ASM impaired ceramide enrichment, engulfment structures, cytoskeletal reorganization, and carrier uptake, which was rescued by supplying this enzyme activity exogenously. Interfering with NHE1 rendered similar outcomes, suggesting that Na 1 /H 1 exchange might provide an acidic microenvironment for ASM at the plasmalemma.
I ntercellular adhesion molecule 1 (ICAM-1) is an immunoglobulin-like transmembrane glycoprotein predominantly present on endothelial cells (ECs). 1, 2 It is overexpressed in vascular pathologies involving inflammation, thrombosis, atherosclerosis, oxidative stress, ischemia-reperfusion, altered blood flow, and diabetes, 1, 2 representing an interesting target for vascular drug delivery. [3] [4] [5] Multivalent engagement of ICAM-1 by anti--ICAM-coated polymer carriers used for targeting of therapeutics results in uptake of said carriers via cell adhesion molecule (CAM)-mediated endocytosis ( Table  I in the online-only Data Supplement). 6 This provides intraendothelial delivery of therapeutics in cell culture and animal models. 3, [7] [8] [9] [10] [11] Knowledge of the regulatory pathways underlying this process is hence valuable for the design of more effective intravascular treatments.
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CAM-mediated endocytosis depends on dynamin, a GTPase involved in budding of clathrin-and caveolar-associated vesicles, yet materials internalized via ICAM-1 do not colocalize with these markers, and their uptake is not affected by inhibiting these routes. 6, 12, 13 CAM-mediated endocytosis requires protein kinase C, but not phosphatidylinositol 3-kinase or phospholipase C, that are involved in macropinocytosis and phagocytosis. 6 It also involves Src kinases and Rho-dependent kinase, leading to actin stress fibers formation, 6 but not the actin cups or microtubules observed in macropinocytosis and phagocytosis. 14, 15 This pathway is also associated with platelet-EC adhesion molecule 1 6 but differs from clathrin-mediated uptake of E-selectin, 16 P-selectin, 17 or vascular cell adhesion molecule 1 (VCAM-1) 18 and caveolar-mediated turnover of thrombomodulin. 19 The ICAM-1 pathway may be related to other nonclassical endocytic routes, such as that of fibroblast growth factors mediated by syndecans, 20 but this remains unexplored.
Upon multivalent engagement by anti-ICAM carriers, ICAM-1 interacts with amiloride-sensitive Na 1 /H 1 exchanger protein NHE1. 21 NHE1 can serve as a cytoskeleton adaptor through ezrin/radixin/moesin proteins and a-actinin, 22 leading to alignment of actin bundles beneath carrier particles. 21 This contributes to formation of membrane engulfing structures and invaginations, leading to internalization of objects ranging from 180 nm to 5 m in diameter, providing a remarkable flexibility for design of drug carriers. 9 It is likely that uptake of these drug carriers by ECs requires not only specialized cytoskeletal structures but also lipid platforms providing reduced diffusion of the involved elements (ICAM-1, NHE1, the cytoskeleton, and signaling molecules). This has been observed during engagement of ICAM-1 by leukocyte  2 integrins, which also involves protein kinase C and Src kinase, actin stress fibers, and specialized lipid domains on the EC surface. 23, 24 However, CAM-mediated endocytosis remains relatively uncharacterized. In this work, we studied the regulatory link between plasmalemma and cytoskeletal elements involved in endocytosis via ICAM-1. We found an unforeseen role for acid sphingomyelinase (ASM) and the sphingomyelin/ceramide pathway in this process, with NHE1 providing a ground for spatial regulation of these events. Our data are consistent with the ability of ECs to internalize relatively large drug carriers bound to ICAM-1, and they also expand the knowledge of the role of the sphingomyelin/ceramide pathway on the function of the vascular endothelium.
Methods antibodies and reagents
Antibodies to human and mouse ICAM-1 were R6.5 and phycoerythrin-LB-2 (Santa Cruz Biotechnology, Santa Cruz, CA) for human and YN1 for mouse samples. 7 Antibodies to platelet-EC adhesion molecule 1, NHE1, VCAM-1, clathrin heavy chain, mannose 6-phosphate receptor (M6PR), ASM, ganglioside GM1, and ceramide were from BD Biosciences (Franklin Lakes, NJ), EMD Chemicals (Gibbstown, NJ), Millipore (Billerica, MA), and Sigma-Aldrich (Saint Louis, MO). Secondary antibodies were from Jackson Immunoresearch (West Grove, PA). Polystyrene-latex beads were from Polysciences (Warrington, PA). BODIPY FL C12-sphingomyelin and Texas Red-labeled phalloidin were from Molecular Probes (Eugene, OR). Human recombinant ASM was provided by Dr Edward Schuchman (Mount Sinai School of Medicine, New York, NY), and neutral sphingomyelinase (SMase) was from Sigma-Aldrich. All other reagents were from Sigma-Aldrich.
Cell Cultures
Human umbilical vein endothelial cells (HUVECs) from Lonza (Walkersville, MD) were cultured in supplemented M-199 medium. 6 Mouse lung ECs were isolated from wild-type C57BL/6 (The Jackson Laboratory, Bar Harbor, ME) or ASM 2/2 mice 25 (provided by Dr Schuchman) using magnetic beads coated with anti-platelet-EC adhesion molecule 1, and cultured in supplemented Dulbecco's modified Eagle's medium. 26 Cells were seeded on 1% gelatin-coated coverslips and treated overnight with 10 ng/mL tumor necrosis factor-a to induce ICAM-1 overexpression. 6
Preparation of Polymer Carriers targeted to Cell surface Markers
Model carriers were prepared by adsorbing antibodies to ICAM-1, VCAM-1, or M6PR on the surface of 4.5  m-diameter (or 100 nm, when indicated) polystyrene beads, as described, 6, 9, 27, 28 rendering 5000 (or 7000) antibody molecules/m 2 , equivalent to 320|000 (or 250) antibody molecules/particle. Alternatively (when indicated), 4.5 m carriers were prepared using a 50:50 mass-ratio mix of anti-ICAM and IgG or recombinant ASM (2500 anti-ICAM molecules/m 2 ).
enrichment of Lipids at sites of iCaM-1 engagement on the endothelial Plasmalemma
Anti-ICAM carriers were incubated for 15 minutes at 37°C with control HUVECs or HUVECs treated with 5 mmol/L methyl--cyclodextrin (to extract cholesterol), 20 mol/L 5-( N-ethyl-N-isopropyl)amiloride (EIPA) (to inhibit NHE1), 50 mol/L imipramine (to inhibit ASM), or a mix of 50 mol/L imipramine and 500 mU/mL neutral SMase (to inhibit ASM while providing SMase activity). Nonbound carriers were washed and cells were fixed. Carrier engulfment by ECs was verified by scanning electron microscopy. In parallel, cholesterol was stained using 50 g/mL filipin, and sphingomyelin was visualized by preincubating HUVECs with 0.2 g/mL BODIPY-sphingomyelin. 9 Ganglioside GM1 and ceramide were immunostained. Cell-bound carriers were identified by phase-contrast microscopy, and enrichment of molecules at these sites was quantified as the fold increase of fluorescence intensity at engulfment structures (2 m above the cell surface) over that of adjacent regions, as described in the online-only Data Supplement.
recruitment of Proteins at sites of iCaM-1 engagement on the endothelial Plasmalemma
Anti-ICAM, anti-VCAM, or anti-M6PR carriers were incubated for 15 or 30 minutes at 37°C with control HUVECs or HUVECs treated with 5 mmol/L methyl--cyclodextrin (to remove cholesterol), 50 mol/L imipramine (to inhibit ASM), a mix of 50 mol/L imipramine and 500 mU/mL neutral SMase (to inhibit ASM while providing SMase activity), 3 mmol/L amiloride or 20 mol/L EIPA (to inhibit NHE1), 0.5 mol/L wortmannin (to inhibit phosphatidylinositol 3-kinase), or 10 mol/L 1-(5-isoquinolinylsulfonyl)-2methyl-piperzine (H-7, to inhibit protein kinase C). Anti-ICAM-coat on carriers was detected by immunofluorescence. ASM, ICAM-1, NHE1, M6PR, and VCAM-1 were also immunostained for fluorescence microscopy. Semiquantitative analysis of the enrichment of these molecules at sites of carrier binding was performed as described above.
The intracellular distribution of ASM was assessed by computing the total number of ASM-positive vesicles (100-300 nm diameter) and those located within 5 m of the nucleus (perinuclear). Peripheral intracellular ASM was calculated as the number of total minus perinuclear ASM-positive vesicles.
Coprecipitation of ASM, a-actinin, and moesin with ICAM-1 was assessed by incubating HUVECs with anti-ICAM magnetic beads for 15 minutes at 37°C as described, 21 followed by recovery of bound beads, protein elution and separation by electrophoresis, and liquid chromatography/mass spectrometry.
actin remodeling and CaM-Mediated endocytosis
Formation of filamentous actin (F-actin) on binding of anti-ICAM carriers to HUVECs over a period of 15 minutes at 37°C, was visualized by fluorescence microscopy using Alexa Fluor 594-phalloidin.
For endocytosis in cell cultures, HUVECs, wild-type mouse lung ECs, or ASM 2/2 mouse lung ECs were incubated at 37°C with anti-ICAM carriers for 30 minutes to allow binding, followed by washing of nonbound carriers and incubation at 37°C for 1 hour to allow endocytosis. Similar tests were performed in 3 mmol/L amiloride, 50 mol/L imipramine, 0.5 mol/L wortmannin, 10 mol/L H-7, or Na 1 -depleted solution (138 mmol/L choline chloride, 5.4 mM KCl, 1 mmol/L CaCl 2 , 1 mmol/L MgCl 2 ). Endocytosis of carriers displaying 50% anti-ICAM surface density was also tested, as well as the effect of cocoating carriers with both anti-ICAM and recombinant ASM, to rescue this activity. After cell fixation, carriers accessible at the cell surface were counterstained using Texas Red-labeled secondary antibody, and the number of carriers internalized per cell was quantified by phase-contrast (total carriers) and fluorescence ( surface-located carriers) microscopy, as described. 6, 9 C57BL/6, caveolin-1 2/2 , and ASM 2/2 mice were anesthetized intraperitoneally with 100/10 mg/kg body weight ketamine/xylazine and injected intravenously with 180 nm anti-ICAM carriers (instead of 4.5 m counterparts that may cause embolization). Intracardial perfusion 3 hours after injection was used to remove circulating carriers and carriers loosely bound the vasculature, and lungs were processed into 80 to 90-nm-thick resin-embedded sections to visualize the pulmonary endothelium by transmission electron microscopy. 9 Endocytosis of anti-ICAM carriers by pulmonary ECs in vivo was semiquantitatively assessed as the number of EC internalized carriers per field, as described. 29 All animal studies conformed to institutional animal care and use committee regulations. 
results

Visualization of Lipid Components at sites of engulfment of anti-iCaM Carriers by eCs
To visualize the cell surface and enrichment of particular molecules during the initial steps of CAM-mediated endocytosis, we looked at the interaction of 4.5 m anti-ICAM carriers with the EC plasmalemma. Fluorescence microscopy showed that within 15 minutes, anti-ICAM carriers bound to ECs and were engulfed (confirmed by scanning electron microscopy; Figure  1A ) by ICAM-1-enriched membrane protrusions (Video I in the online-only Data Supplement; Figure 1B ).
Next, we visualized lipid-raft components, because ICAM-1 cross-linking with antibodies elicits its association with detergent-resistant membrane fractions. 30 Cholesterol, sphingomyelin, and ganglioside GM1 were enriched by 1.50.05-fold, 2.50.1-fold, and 3.20.1-fold, respectively, in regions of carrier engulfment versus adjacent "background" areas ( Figure 1C ; Figure 
effect of impairing asM on CaM-Mediated endocytosis
The role of cholesterol/ sphingomyelin-rich domains and NHE1 (a linker between CAM-mediated endocytosis and the cytoskeleton 21, 22 ) in the first stages of anti-ICAM carrier uptake suggests involvement of ASM. This enzyme hydrolyzes sphingomyelin into ceramide, 31, 32 which supports large lipid domains, 33, 34 favors vesiculization, [34] [35] [36] and promotes cytoskeletal rearrangement 37,38 associated with several physiological functions. 39 ASM inhibition by imipramine decreased endothelial endocytosis of anti-ICAM carriers (38% reduction; Figure 2A ). Endocytosis was also affected by inhibiting NHE1 with amiloride (86% reduction), but not by inhibiting caveolar-mediated endocytosis with filipin (7% increase) or by reducing anti-ICAM surface density on carriers by 50%, which affected only binding (59% reduction; data not shown). Confirming a role for ASM, endothelial endocytosis of anti-ICAM carriers was also impaired in ECs isolated from ASM 2/2 mice (75% reduction versus wild-type; Figure 2A ), yet uptake was rescued by cocoating recombinant ASM onto anti-ICAM carriers (147% uptake compared with wild-type; Figure 2A ).
This finding was validated in vivo after intravenous injection of anti-ICAM carriers (180 nm, to avoid potential embolization by 4.5 m carriers) in wild-type, caveolin-1 2/2 , or ASM 2/2 mice, followed by visualization and semiquantitative estimation of carrier endocytosis by pulmonary ECs (a preferential target for anti-ICAM carriers) using transmission electron microscopy, as recently described. 29 In agreement with cell culture experiments, endocytosis of anti-ICAM carriers was inhibited in ASM 2/2 mice but not in caveolin-1 2/2 mice (12.2% and 92.8% of wild-type mice, respectively; Figure 2B ). This verifies that ASM is required for endocytosis of anti-ICAM carriers by the vascular endothelium.
recruitment of asM, Ceramide Generation, and role of NHe1 at sites of engulfment of anti-iCaM Carriers by eCs
We then determined whether ASM is involved in CAM-mediated endocytosis through ceramide generation at sites of carrier engulfment by ECs. Immunofluorescence showed that in the absence of anti-ICAM carriers, most ASM localized in the perinuclear region of cells, with a fraction located to vesicular-like structures (41.84.7 vesicles/ cell; Figure IV Figure 3A) . Confirming the specificity of this, ASM was not recruited to sites of carrier binding to VCAM-1, another CAM involved in inflammation, or M6PR, involved in clathrin-mediated transport of ASM ( Figure 3A ). Anti-M6PR carriers induced recruitment of neither ICAM-1 nor NHE1, but they did recruit clathrin heavy chain ( Figure V in the online-only Data Supplement), validating this model. ASM staining colocalized with ICAM-1 at areas of anti-ICAM carrier engulfment (85.12.9% of carriers; Figure  3B ), where ASM appeared within ICAM-1-lined vesicular structures ( Figure 3B, 163 ). However, opposite to a-actinin or moesin, ASM did not coimmunoprecipitate with ICAM-1 ( Table II in the online-only Data Supplement). This suggests that upon release from intracellular vesicles, the enzyme simply interacts with sphingomyelin at neighboring sites of the plasmalemma rather than ICAM-1.
Importantly, ceramide also became enriched at these sites (3.50.01-fold over adjacent regions; Figure 4A ; Figure VIA in the online-only Data Supplement), which was impaired by inhibiting ASM with imipramine (23.6% decrease), and rescued by exogenously added neutral SM (92% of control). Similarly, EIPA (an amiloride derivative that specifically inhibits NHE1 21 ) also reduced ceramide enrichment (35.6% decrease), suggesting that this ion exchanger, which mediates H 1 efflux, may provide the acidic environment for ASM activity at the plasmalemma. Indeed, ASM staining also colocalized with NHE1 (85.33.4% of carriers; Figure 4B ), and both ASM inhibition with imipramine and NHE1 inhibition with EIPA affected similarly carrier engulfment (37.9% and 36.6% decrease, respectively; Figure 4C ; Figure VIB in the online-only Data Supplement), which was rescued by exogenous neutral SMase (87.8% of control). Furthermore, Na 1 depletion (to impair Na 1 /H 1 transport) led to a 93% reduction in CAM-mediated endocytosis (Figure 2A ). This suggests that NHE1 may connect the ASM-mediated sphingomyelin/ ceramide pathway to CAM-mediated endocytosis.
effect of impairing asM on CaM-Mediated actin rearrangement
As described for other systems, [33] [34] [35] [36] ASM-mediated production of ceramide upon ICAM-1 engagement may contribute to formation of lipid domains (Figures 1 and 4) and vesiculization, resulting in endocytosis (Figure 2 ). This pathway is also known to promote cytoskeletal rearrangement, 38 a requirement for CAM-mediated uptake. 6, 9, 21 In accord with this, ASM inhibition by imipramine hindered formation of actin stress fibers induced by anti-ICAM carriers ( Figure 5A ), as previously observed in the case of NHE1 inhibition by amiloride or EIPA. 21 Imipramine did not affect ASM recruitment to carrier-binding sites (93.45% of control), yet it inhibited uptake of anti-ICAM carriers (Figure 2A) , suggesting that ASM recruitment preceded ICAM-1-dependent cytoskeletal rearrangement. Confirming this, inhibition of protein kinase C, which regulates actin stress fiber formation by CAM-mediated endocytosis, did not affect ASM recruitment to ICAM-1 binding sites, but inhibited carrier uptake ( Figure  5B ). In contrast, these events were independent of phosphatidylinositol 3-kinase ( Figure 5B) , previously shown to play no role in CAM-mediated uptake. 6 discussion Binding of anti-ICAM carriers to endothelial ICAM-1 leads to intracellular transport of said carriers via CAM-mediated endocytosis ( Table I in the online-only Data Supplement). 6, 9 This pathway supports delivery of therapeutics into the vascular endothelium by means of carrier particles ranging from 180 nm to several micrometers in diameter 6, 9 and shows regulatory elements (signaling molecules, cytoskeletal reorganization 6,21 ) reminiscent of those elicited on ICAM-1 engagement by leukocytes during inflammation. [40] [41] [42] Here, we found that this process occurs at specialized lipid domains on the EC plasmalemma, where anti-ICAM carriers colocalized with ICAM-1-positive engulfment structures. This occurred in areas enriched in cholesterol, sphingomyelin, and gangliosides and was inhibited by disrupting said domains by cholesterol chelation. Although this was expected, we found an unforeseen contribution by ASM and the sphingomyelin/ceramide pathway toward the formation of ICAM-1-enriched membrane protrusions and CAM-mediated endocytosis. ICAM-1 engagement led to ASM redistribution from perinuclear regions to plasmalemma sites where engulfment structures formed. ASM inhibition impaired ceramide enrichment at carrier-binding sites, actin reorganization, and carrier endocytosis, which was rescued by supplying this activity exogenously. Based on our data, we speculate that this enzyme is exocytosed from lysosomal compartments, yet this remains to be tested. It is known that lysosomes carrying ASM can be exocytosed, 36 providing a possible mechanism for our observation. Indeed, exocytosis of lysosomal ASM requires increased intracellular Ca 21 , 43 a phenomenon involved in CAM-mediated endocytosis. 21 Ceramide also accumulated at areas of endothelial engulfment of anti-ICAM carriers, in accord with the presence of sphingomyelin and ASM, and inhibition of ceramide enrichment at these sites resulted in poor engulfment. Although the ceramide type associated with the ICAM-1 pathway remains to be elucidated, several ceramides affect the molecular and biophysical features of the plasmalemma, for instance, by promoting the formation of large lipid domains, affecting membrane function. 33, 34 Ceramide production by ASM at the outer leaflet of the plasma membrane also favors vesiculization 34, 36 and promotes cytoskeletal rearrangement, 38 suggesting that a similar pathway may contribute to formation of engulfment structures and vesicles supporting uptake of anti-ICAM carriers by ECs, as observed in this work.
Sphingomyelinase-mediated formation of ceramide domains at the plasmalemma is associated with phosphorylation and redistribution of actin-adapters of the ezrin/radixin/moesin family, followed by conversion of ceramide into sphingosine-1-phosphate and hyperphosphorylation of ezrin/radixin/ moesins, finally culminating in the formation of membrane protrusions. 44 ICAM-1 redistributes to detergent-resistant membrane fractions on cross-linking with antibodies, and it coprecipitates with ezrin/radixin/moesin proteins, 24 as also observed here. Thus, it is possible that CAM-mediated endocytosis proceeds through a similar mechanism.
NHE1 might provide a bridge among ICAM-1 engaged by anti-ICAM carriers, ASM activity and the sphingomyelin/ ceramide pathway, and the reorganization of the actin cytoskeleton supporting carrier engulfment and endocytosis. NHE1 is involved in cytoskeletal rearrangement 22 and may cross-link actin filaments to the ICAM-1 cytosolic domain. 21 Its ion exchange activity also regulates elasticity at the endothelial surface, 45 explaining engulfment and endocytosis of micrometer-sized objects targeted to ICAM-1. Because ICAM-1 interacts with NHE1 upon binding of anti-ICAM carriers, 21 and because of the directionality of NHE1 ion exchange (H 1 efflux), 21, 46 NHE1 might create an acidic microenvironment at ICAM-1 engagement regions. Although there is controversy concerning the pH range at which exocytosed ASM can exert activity, 31, 36 NHE1 contribution would explain how this acidic enzyme can display activity at the otherwise neutral extracellular environment and how ECs might regulate ceramide production with spatial precision. A similar function of NHE1 has been shown for other pH-sensitive enzymes. 46 Particularly, NHE1 inhibition with cariporide ameliorates cisplatin-induced, ASM-dependent generation of ceramide. 47 Altogether, these data (complemented by data reported previously) suggest a model by which engagement of ICAM-1 in lipid domains enriched in sphingomyelin induces exocytosis of ASM to these areas of the endothelial plasmalemma ( Figure 6 ). Engaged ICAM-1 forms a complex with NHE1, resulting in local acidification and ASM-driven hydrolysis of sphingomyelin into ceramide. This favors actin polymerization and cytoskeleton remodeling, stabilizes the engagement platform by restricting molecular diffusion and providing cytoskeletal anchorage, regulates membrane deformability, and favors formation of engulfment structures and endocytic vesicles. These events support the ability of ECs to internalize relatively large drug carriers targeted to ICAM-1, as opposed to classical clathrin-or caveolar-mediated endocytosis. Results shown here and previously 6, 9, 11, 27, 48 also indicate that multivalent binding to ICAM-1 is required to induce these events, yet this is still achievable with carriers displaying different antibody surface densities, emphasizing the design flexibility of this strategy.
These results hold relevance regarding inflammation and vascular pathologies. ECs constitutively secrete ASM, whose activity increases in inflammation and accelerates progression of atherosclerotic lesions. [49] [50] [51] Ceramide production by sphingomyelinases has also been associated with increased redox signaling and leukocyte attachment to brain endothelium. 52, 53 Leukocyte influx into alveoli is decreased on ASM inhibition, 54 and metabolic imbalances causing high levels of ceramide can lead to higher leukocyte levels in tissue. 55 Leukocyte transmigration across the endothelium has been linked to cholesterol-, sphingomyelin-, or ganglioside-rich areas in lipid rafts. 30 Hence, our data showing redistribution of ASM to endothelial structures where ICAM-1 is engaged, along with enrichment of ceramide in these regions, are consistent with this literature.
These results advance current knowledge on the regulation of CAM-mediated endocytosis, which may provide new tools for modulation of intraendothelial therapies, and also underscore the implication of sphingomyelin/ceramide signaling in the vascular function.
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